Tagged with Brazil

LatAm A roundup of some of the latest stories from Latin American pharma and healthcare, including Sanfer’s acquisition of Columbia-based injectables manufacturer Vitalis; medicine shortages in Colombia, and Chile’s move towards universal primary health coverage with support from the World Bank.   ACON Investments Signs Definitive Agreement to Sell Vitalis to…

Brazil Brazil’s ANVISA is commonly recognised as LatAm’s leading national medicines regulator and is defined by the Pan American Health Organization (PAHO) as a National Regulatory Authority of Regional Reference (NRAr) for medicines and vaccines. As part of our Transformative 2023: Regional Pharma Trends report, PharmaBoardroom’s Patrick Burton explores some of the key recent…

Brazil The latest pharma news from Brazil, including the partnership between Biophytis and Innovation Solutions Pharma; Merck’s 100 years in Brazil; Eurofarma’s USD 100 million biotech investment, and GSK’s green light from ANVISA.   Biophytis and Innovation Solutions Pharma Sign a Partnership Agreement to Accelerate Market Access for Sarconeos in Brazil…

Brazil Part of PharmaBoardroom’s new country-focused series on market access and health technology assessment (HTA), this piece is focused on HTA Dossiers and Data requirements in the Brazilian pharma market today. Buy The Pharma Legal Handbook: Market Access & HTA – Brazil here for £359.   HTA DOSSIERS Have local authorities published…

LatAm A roundup of some of the latest news from Latin American pharma, including Acino’s acquisition of M8 Pharmaceuticals; AstraZeneca’s growth in Mexico; Neuraxpharm’s expansion into Brazil and Mexico, and Columbia’s decision to issue a compulsory license for GSK/ViiV’s HIV treatment.   Colombia set to issue a compulsory license for an…

Brazil The DIA Global Annual Meeting 2023 hosted DIA’s first regulatory Town Hall fully dedicated to one regulator from Latin America, as leadership from Brazil’s Health Regulatory Agency, ANVISA, shared updates on the country’s regulatory priorities, the agency’s strategic priorities, and local trends, as well as ongoing regulatory convergence and collaboration initiatives. This…

Brazil The latest pharma news from Brazil, including Daiichi Sankyo’s new plant; Bristol Myers Squibb’s re-entry into Brazil’s cardiology market; the Anvisa approval of HIV prevention drug, cabotegravir; Merck’s gamble on the Brazilian obesity market and Novo Nordisk’s patent extension denial.   Japan’s Daiichi Sankyo invests $80 million to expand Brazilian…

Brazil Henrique Tada of ALANAC, the association that brings together Brazil’s domestic pharma companies, comments on the evolution of the Brazilian generics, biosimilars, and value-added medicines markets, local laboratories’ internationalisation efforts, and the policy reforms he hopes that the country’s new administration will roll out.   The pandemic has given us…

LatAm In a wide-ranging interview, AbbVie’s Flavio Devoto outlines some of the key access challenges and opportunities in the diverse Latin American pharma market, his approach to being a transformational leader while balancing demands from headquarters with realities on the ground, and the enduring importance of LatAm to the global group.…

Brazil The latest from Brazilian Pharma, including the controversial proposal to transform Brazil’s regulatory agency, ANVISA; Ease Labs’s canabidiol approval, Biolab’s international expansion ambitions and Eurofarma’s multiple myeloma deal.    ANVISA’s autonomy challenged by Congress (Regulatory Focus) After the swearing in Brazilian’s President Luiz Inácio Lula da Silva earlier this year,…

LatAm Guilherme Marques, president of Siemens Healthineers LatAm, discusses the health tech giant’s regional strategy, covering how the firm rides out the region’s economic and political storms, its participation in disease screening campaigns, digitalisation uptake, oncology integration, and much more.   Despite the uncertainty of [LatAm] markets – due to inflation,…

Americas In 2019 the pharma industry financed some 700 clinical studies in Latin America with investments of more than USD one billion and according to FIFARMA, the leading association of innovators in the region, LatAm currently supports about 10 percent of the world’s clinical research. Local industry leaders discuss the advantages…